ATE329601T1 - Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels - Google Patents

Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels

Info

Publication number: ATE329601T1
Authority: AT; Austria
Prior art keywords: deficiency; prevention; treatment; administration; vitamin
Prior art date: 2001-04-25

Application number

AT02720247T

Other languages

English (en)

Inventor

Andrew Mccaddon

Original Assignee

Cobalz Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-22

Publication date

2006-07-15

2001-04-25 Priority claimed from GB0110336A external-priority patent/GB0110336D0/en

2001-08-22 Priority claimed from GB0120363A external-priority patent/GB0120363D0/en

2002-04-22 Application filed by Cobalz Ltd filed Critical Cobalz Ltd

2006-07-15 Application granted granted Critical

2006-07-15 Publication of ATE329601T1 publication Critical patent/ATE329601T1/de

Links

239000000203 mixture Substances 0.000 title abstract 3
208000002670 vitamin B12 deficiency Diseases 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 2
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 3
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
230000003834 intracellular effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010012289 Dementia Diseases 0.000 abstract 1
108010024636 Glutathione Proteins 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
239000005864 Sulphur Substances 0.000 abstract 1
229930003779 Vitamin B12 Natural products 0.000 abstract 1
230000005856 abnormality Effects 0.000 abstract 1
230000008238 biochemical pathway Effects 0.000 abstract 1
238000011260 co-administration Methods 0.000 abstract 1
229960003180 glutathione Drugs 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000036542 oxidative stress Effects 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1
239000011715 vitamin B12 Substances 0.000 abstract 1
235000019163 vitamin B12 Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Psychiatry (AREA)

AT02720247T 2001-04-25 2002-04-22 Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels ATE329601T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0110336A GB0110336D0 (en)	2001-04-25	2001-04-25	A method for treating an individual with metabolic evidence of Vitamid 12 deficiency and co-existing dementia or other neuropsychiatric abnormality
GB0120363A GB0120363D0 (en)	2001-08-22	2001-08-22	A method for treating an individual with low intracellular glutathione and/or metabolic evidence of vitamin B12 deficiency and co-existing dementia or other

Publications (1)

Publication Number	Publication Date
ATE329601T1 true ATE329601T1 (de)	2006-07-15

Family

ID=26246012

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02720247T ATE329601T1 (de)	2001-04-25	2002-04-22	Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels

Country Status (9)

Country	Link
US (2)	US7709460B2 (de)
EP (1)	EP1381373B1 (de)
JP (1)	JP2004526793A (de)
CN (1)	CN1537009A (de)
AT (1)	ATE329601T1 (de)
CA (1)	CA2445512C (de)
DE (1)	DE60212365T2 (de)
ES (1)	ES2269671T3 (de)
WO (1)	WO2002087593A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10311089A1 (de) *	2003-03-13	2004-09-23	Roche Diagnostics Gmbh	Differenzialdiagnostik und Monitoring von Vitamin B12-, Vitamin B6- und Folsäure-Störungen mittels vier unabhängiger Messgrößen
RU2433819C2 (ru) *	2004-11-09	2011-11-20	Хилл'С Пет Ньютришн, Инк.	Применение антиоксидантов для модуляции генов
AR057623A1 (es)	2005-11-28	2007-12-05	Omega Bio Pharma H K Ltd	Materiales y metodos para el tratamiento de las infecciones virales
EP1800675B1 (de)	2005-12-23	2011-05-18	N.V. Nutricia	Zusammensetzung enthaltend mehrfach ungesättigte Fettsäuren, Proteine, Mangan und/oder Molybden und Nukleotide/Nukleoside, zur Behandlung von Demenz
US7754700B2 (en) *	2006-04-24	2010-07-13	Trager Seymour F	Composition and methods for alleviating symptoms of neurotoxicity
ATE508740T1 (de) *	2006-06-07	2011-05-15	Kyowa Hakko Bio Co Ltd	Mittel zur verringerung von müdigkeit
US7812042B2 (en) *	2006-09-22	2010-10-12	Kent State University	Pharmaceutical compositions and therapeutic applications for the use of a novel vitamin B12 derivative, N-acetyl-L-cysteinylcobalamin
US7972633B2 (en) *	2007-02-07	2011-07-05	Applied Cognitive Sciences, LLC	Nutritional supplements for healthy memory and mental function
GB0723972D0 (en) *	2007-12-07	2008-01-23	Queen Mary & Westfield College	Use of vitamin B12
EP2303019A4 (de) *	2008-06-25	2013-07-17	Bermans S Iskandar	(6s)-5-methyltetrahydrofolsäure zur behandlung von gewebeläsionen
EP2575825A4 (de) *	2010-02-12	2014-01-01	Alexander Vuckovic M D Llc	Zusammensetzungen und verfahren zur behandlung von depression
WO2011106378A2 (en) *	2010-02-24	2011-09-01	Emisphere Technologies, Inc.	Oral b12 therapy
EA201370008A1 (ru) *	2010-07-01	2013-06-28	Айсис Инновэйшн Лимитид	Лечение когнитивных нарушений
US9040082B2 (en)	2011-06-24	2015-05-26	K-Pax Pharmaceuticals, Inc.	Compositions and methods for treatment of chronic fatigue
JP6015158B2 (ja) *	2012-06-22	2016-10-26	大正製薬株式会社	トランスコバラミンｉｉ遺伝子産物量調整剤
BR112017025499A2 (pt) *	2015-05-28	2018-08-07	Baylor College Medicine	benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
US20160367620A1 (en)	2015-06-19	2016-12-22	Harry B. Demopoulos	Glutathione
WO2018144088A1 (en)	2016-11-03	2018-08-09	Alexander Vuckovic, M.D., Llc	Compositions and methods for treating depression
EP3406622A1 (de) *	2017-05-24	2018-11-28	Albert-Ludwigs-Universität Freiburg	Cobalaminderivate und deren verwendung zur behandlung von krankheiten durch mangelnde vitamin-b12-versorgung
FR3068603B1 (fr) *	2017-07-10	2020-01-03	Nuribiol	Complement alimentaire pour proteger la fertilite feminine et masculine
IL275479B2 (en)	2017-12-21	2026-01-01	Univ Osaka	Therapeutic material for nervous system disease
EP3935581A4 (de)	2019-03-04	2022-11-30	Iocurrents, Inc.	Datenkompression und -kommunikation mit maschinenlernung
CA3162095A1 (en)	2019-11-21	2021-05-27	James A. Garegnani	Vitamin b12 compound supplementation methods and compositions
FR3119093B3 (fr) *	2021-01-27	2023-02-10	Nestle Sa	Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle
US20220387474A1 (en) *	2021-06-07	2022-12-08	Peter Nagele	Supplement compositions for nitrous oxide patients

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US945772A (en) *	1909-03-17	1910-01-11	Hoard E	Mop.
US3130189A (en)	1959-04-06	1964-04-21	Merck & Co Inc	Hydroxocobalamin-glutathione
US4940658A (en) *	1986-11-20	1990-07-10	University Patents, Inc.	Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency
US5807832A (en) *	1987-06-09	1998-09-15	Biotech Australia Pty Limited	Oral delivery of biologically active substances bound to vitamin B12
US5668117A (en) *	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6787527B1 (en) *	1994-11-10	2004-09-07	Duke University	Methods of preventing and treating HIV infection
US6008190A (en) *	1994-12-15	1999-12-28	California Institute Of Technology	Cobalt Schiff base compounds
WO1998011900A2 (en)	1996-09-18	1998-03-26	Sarill William J	Compositions containing cobalamin and amino acids
US6008221A (en)	1996-11-06	1999-12-28	Bristol-Myers Squibb Company	Method for treating Alzheimer's disease with folic acid
JP4578578B2 (ja) *	1997-01-13	2010-11-10	エモリー、ユニバーシティ	インフルエンザ感染の治療用化合物及びそれらの組み合わせ
EP0891719A1 (de) *	1997-07-14	1999-01-20	N.V. Nutricia	Narungszusammensetzungen mit Gehalt an Methionin
US6207190B1 (en) *	1998-08-13	2001-03-27	Chronorx, Llc	Dosage forms for the treatment of the chronic glaucomas
ES2187115T3 (es)	1999-01-20	2003-05-16	Nutricia Nv	Preparado para lactantes.
GB9906740D0 (en)	1999-03-23	1999-05-19	Kilgowan Limited	Oral combinations of hydroxocobalamin and folic acid
CA2377232A1 (en) *	1999-06-11	2000-12-21	Henceforth Hibernia, Inc.	Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
US6562869B1 (en) *	1999-09-23	2003-05-13	Juvenon, Inc.	Nutritional supplement for increased energy and stamina
AU8003800A (en)	1999-10-08	2001-04-23	Joyce Corinne Bechthold	Methods and compositions for treating neurobehavioral disorders
DE10027968A1 (de)	2000-06-08	2001-12-13	Asta Medica Ag	Mittel zur Therapie von Demenzen
WO2002002190A2 (en) *	2000-07-05	2002-01-10	Johns Hopkins School Of Medicine	Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

2002
- 2002-04-22 ES ES02720247T patent/ES2269671T3/es not_active Expired - Lifetime
- 2002-04-22 CA CA2445512A patent/CA2445512C/en not_active Expired - Fee Related
- 2002-04-22 US US10/475,898 patent/US7709460B2/en not_active Expired - Lifetime
- 2002-04-22 EP EP02720247A patent/EP1381373B1/de not_active Expired - Lifetime
- 2002-04-22 WO PCT/GB2002/001843 patent/WO2002087593A1/en not_active Ceased
- 2002-04-22 AT AT02720247T patent/ATE329601T1/de active
- 2002-04-22 DE DE60212365T patent/DE60212365T2/de not_active Expired - Lifetime
- 2002-04-22 CN CNA028107241A patent/CN1537009A/zh active Pending
- 2002-04-22 JP JP2002584938A patent/JP2004526793A/ja active Pending
2010
- 2010-02-16 US US12/706,411 patent/US20110077194A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1381373B1 (de)	2006-06-14
US7709460B2 (en)	2010-05-04
WO2002087593A1 (en)	2002-11-07
ES2269671T3 (es)	2007-04-01
EP1381373A1 (de)	2004-01-21
JP2004526793A (ja)	2004-09-02
CA2445512A1 (en)	2002-11-07
CN1537009A (zh)	2004-10-13
US20040157783A1 (en)	2004-08-12
DE60212365D1 (de)	2006-07-27
DE60212365T2 (de)	2007-05-31
US20110077194A1 (en)	2011-03-31
CA2445512C (en)	2010-10-12

Legal Events

Date

Code

Title

Description

2006-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1381373

Country of ref document: EP

Publication	Publication Date	Title
ATE329601T1 (de)	2006-07-15	Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels
NO20050807L (no)	2005-02-15	Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
DE60331537D1 (de)	2010-04-15	Kombinationen zur behandlung von multiplem myelom
GB0201508D0 (en)	2002-03-13	Organic compounds
CY1108342T1 (el)	2014-02-12	Ανοσορρυθμιστικοι ολιγοσακχαριτες
DE60216830D1 (de)	2007-02-01	Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EP1478371A4 (de)	2007-11-07	Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen
NO20061245L (no)	2006-05-31	Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon
BR0116370A (pt)	2003-12-09	Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0312232A (pt)	2005-05-10	Inibidores de caspases e seus usos
BR0307508A (pt)	2004-12-07	Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DE59706808D1 (de)	2002-05-02	Verwendung von 7-(2-oxa-5,8-diazabicyclo 4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
UY27993A1 (es)	2004-03-31	Derivados de 4-pirrolidino-fenil-bencil eter
AR045004A1 (es)	2005-10-12	Composiciones farmaceuticas que comprenden 11-piperazin-1-ildibenzo[b,f][1,4]tiazepina
NO20044530L (no)	2004-10-21	Fremgangsmate for behandling av kognitive forstyrrelser
BRPI0407178A (pt)	2006-02-07	Composição farmacêutica osteogênica
BR0311903A (pt)	2005-06-07	Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
BRPI0414518A (pt)	2006-11-07	composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
ECSP045405A (es)	2005-01-03	Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
ATE458004T1 (de)	2010-03-15	Osteoprotegerin in milch
AU2003245989A8 (en)	2004-01-23	Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
DE3775854D1 (de)	1992-02-20	Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.
NO20060655L (no)	2006-06-16	2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn
DK1497250T3 (da)	2008-12-01	Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
ATE431148T1 (de)	2009-05-15	Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme